AstraZeneca PLC (NASDAQ:AZN) said on September 28 that it will make a $2 billion equity investment in Summit Therapeutics, Inc. (NASDAQ:SMMT) and run joint trials of the two companies’ cancer drugs.
The money buys preferred shares convertible into common stock at an equivalent of $18.36 each, a premium to Summit’s September 28 close of $15.48. Summit is worth about $13 billion, and the $18.36 conversion price buys roughly 109 million shares. That is about 12% of the company once those shares exist.
READ ALSO: Summit Therapeutics (SMMT) Soars 28% on Ivonescimab Progress
AstraZeneca Gets a Claim on the Drug Without Buying the Company:
AstraZeneca is not acquiring Summit, and it is not licensing the drug outright. It is taking convertible preferred stock at a premium, alongside a clinical collaboration to test Summit’s ivonescimab with AstraZeneca’s sonesitatug vedotin across several tumor types. If the combination works, AstraZeneca is already a large shareholder. If it does not, the loss is capped at $2 billion, which is under 1% of AstraZeneca’s market value.
Scale makes that possible. AstraZeneca is worth about $262 billion. Ivonescimab is the asset being bet on. It is in late-stage trials across lung and bladder cancers among several others. That is an unusually broad program for a company of Summit’s size.
Breadth like that is expensive. Running parallel late-stage programs costs more than a company with no approved product can fund alone, which is the practical reason this deal exists.
It is also why the partner matters as much as the money. AstraZeneca already runs trials across these tumor types, and that infrastructure is harder to buy than capital is.
DON’T MISS: AstraZeneca (AZN)’s Lung Drug Delivers the Good News its Pipeline Needed
The Drug Has Not Cleared the Trial That Matters:
A price above the market usually signals confidence, and here it partly reflects the structure instead. AstraZeneca is taking preferred rather than common stock, and the companies have not detailed what rights attach to it. A conversion price above the market can reflect those terms as much as a view on what Summit is worth.
It also buys something harder to price. A partner of this size validates the science to every other investor looking at the company, and that signal has value whether or not the drug eventually works.
The drug itself remains unproven where it matters. Ivonescimab has generated encouraging data and has not yet cleared a Phase III readout that would settle the argument in the United States. The FDA has set a decision date of November 14 for its use in EGFR-mutant lung cancer, so AstraZeneca is buying in six weeks before an answer arrives. Summit reported a loss of $1.11 a share over the past twelve months.
Its shares are also lower than a year ago, and the stock has not recovered the ground it lost after earlier data.
For AstraZeneca, the risk is different in kind. The company has said it needs pipeline depth as older products approach patent expiry. Buying a stake in Summit costs far less than buying Summit outright, and it secures a claim on the drug without committing to the company that owns it.
Conclusion:
The structure is well judged for the buyer, because convertible preferred stock at a small fraction of market value gives AstraZeneca a claim on the upside while capping what it can lose. Summit gets capital and a partner with global trial infrastructure it could not build alone. However, everything here still depends on a drug that has not completed the readout that matters, and Summit traded lower for most of the year while investors waited for it.
What the Price Assumes:
AstraZeneca closed at $161.47 on September 30, slightly lower than a year ago. Summit opened above the $18.36 conversion price the morning after the announcement and closed well below it. At $16.91, it sits about 8% short of that level.
AstraZeneca grew revenue 6.40% last quarter and earnings 2.30%. The shares trade near 25 times trailing earnings but under 15 times next year’s estimates, a gap that points to trailing profit held down by charges rather than to a coming surge in growth.
At under 15 times forward earnings, a buyer is underwriting a pipeline that replaces what patent expiries take away. This deal is one attempt at that, and the drug behind it has not yet delivered the readout that would settle what it is worth.
Market Sentiment:
AstraZeneca PLC was held by 55 hedge funds with a combined stake value of about $5.5 billion at the end of Q2 2026 in the Insider Monkey database. This is down from 56 hedge fund holders with a cumulative investment value of around $5.5 billion in the previous quarter.
READ NEXT: Amgen (AMGN) Sells its Deerfield Campus for $151 Million and Leases it Back and Citigroup (C) Lines Up a $3 Billion Banamex IPO for January
This article is originally published at Insider Monkey.
Hedge Fund Resource Center